EZURPIMTROSTAT AUTOPHAGY BLOCKER, A PALMITOYL-PROTEIN THIOESTERASE 1 (PPT1) INHIBITOR, AND ATEZOLIZUMAB/BEVACIZUMAB TRIPLE COMBINATION REGIMEN ENHANCES ANTITUMOR EFFICACY IN HEPATOCELLULAR CARCINOMA
<div><p><b>Background: </b>Immune checkpoint therapies combination with anti-VEGF is the standard-of-care in first-line of hepatocellular carcinoma (HCC). However, only 30 % of patients present a response to first line therapy. Autophagy inhibitors were recently spotted out as a potential robust strategy to promote antigen presentation and therefore reinforce immune checkpoint inhibitors (ICIs) potency conducting to strong anti-tumoral response.